Journal: medRxiv

Article Title: Complement-dependent virion lysis mediated by dengue-Zika virus cross-reactive antibodies correlates with protection from severe dengue disease

doi: 10.1101/2024.06.03.24308395

Figure Lengend Snippet: (A-D) Pre-infection plasma samples prior to DF (green; n=31) vs. DHF/DSS (gold; n=33) were incubated with mature DENV2, mature DENV3, ZIKV, and YFV virions. (A,B) Left panel, 1:10 dlution of plasma; right panel, 1:30 dilution of plasma. (E) Pre-inapparent (blue circles; n=30) and pre-symptomatic (orange circles; n=29) secondary DENV3 infection plasma samples were incubated with ZIKV virions. After incubation with plasma samples in the presence of guinea pig complement, mixtures were freeze-thawed once, followed by RNAse A digestion and RNA extraction from intact virions. Virion lysis was quantified by measuring viral RNA via RT-qPCR (to measure the number of genome copies) and calculated as percentage (%) of virion lysis as described in Methods. Shown are median NT 50 (middle line), 25 th to 75 th percentile (box), and 5 th to 95 th percentile (whiskers) as well as the raw data (points). Asterisks indicate Benjamini-Hochberg-adjusted p-values for Mann-Whitney U tests (****p < 0.0001, and ns, non-significant).

Article Snippet: Standard curves were prepared using seven 10-fold dilutions of a DENV2 8891 synthetic fragment, DENV3 UNC3009 in-vitro transcribed RNA, ZIKV RNA standard (ATCC VR-3252SD) or YFV synthetic RNA standard (ATCC VR-3253SD).

Techniques: Infection, Clinical Proteomics, Incubation, RNA Extraction, Lysis, Quantitative RT-PCR, MANN-WHITNEY

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: Evolution of anti-flavivirus antibodies in a ZVD case (Z3) with few cross-reactions. Original data after cutoff subtraction ( left panels , corresponding to step 2 of Table ) and processed final scores (“Data reduction,” with a score cutoff of 1, right panels , corresponding to step 6 of Table ), for IgM and IgG, with or without urea treatment, are shown. Results from sera taken 10–233 days post first symptom (dpfs) are shown). Probable cross-reactions are shown as arrows . MFI Median Fluorescence Intensity. X -axis antigens are whole virus (“WV”), NS1 or recombinant envelope (“env” or “E”), CHIKV antigens are recombinant E1 protein, wild type (“wt”) and mutated (“m”) from two different manufacturers. DENV antigens are WV and NS1 for each serotype, and summed. ZIKV antigens included recombinant E from two different manufacturers. WNV antigens included WV from two manufacturers (See “ ”)

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques: Fluorescence, Virus, Recombinant

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: Avidity indices (AI; ratio of MFI after and before urea, Y -axis) of the antibody reactions of selected antigens with sera from patients with DF ( n = 61) and ZVD ( n = 43). Upper frames IgM, lower frames IgG. Each frame shows the AIs for a DENV, ZIKV, or TBEV antigen, either WV (WV) or NS1. AIs were not calculated if the reactivity of urea untreated bead was less than 300 MFI. Sera with such results are shown as −0.1 on the Y -axis. Only results with selected antigens are shown

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques:

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: Antibody evolution in a multiply sampled DF case (D51). Avidity index (AI) was calculated for DENV NS1 IgG. See legend of Fig. for further explanations

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques:

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: Extent and frequency of probable cross-reactions, represented as the average MFI ratio between heterologous, recipient, flavivirus antigen (”To”), and donor flavivirus (”From”) signal, for DENV WV + NS1 and for ZIKV NS1, respectively. Only cross-reactions of more than 100 MFI were included. Error bars denote standard error of mean. See legend of Fig. for further explanations. Results from patients with known YFV and TBEV vaccinations were excluded

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques:

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: ZIKV/DENV antibody discrimination in the four main computational steps

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques:

Journal: Medical Microbiology and Immunology

Article Title: Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections

doi: 10.1007/s00430-017-0517-y

Figure Lengend Snippet: Blood donor sera which reacted strongly with ZIKV NS1. a A blood donor serum reactive in IgG. b A blood donor serum reactive in IgM. For abbreviations, see the legend of Fig.

Article Snippet: DENV WV and NS1 reactions summed as DENVXWV and DENVXNS1, respectively; ZIKV; WV (ZeptoMetrix, Buffalo, NY, USA), NS1, baculo recombinant E (E; Aalto [ENV A] and Meridian Life science, Inc. Memphis, Tennessee, USA)[ENV M], yellow fever virus (YFV) NS1 and WV (ZeptoMetrix); tick-borne encephalitis virus (TBEV) WV (Jena Bioscience, Jena, Germany) and NS1; West Nile virus (WNV) NS1, E coli recombinant E (Jena*), WV (East Coast Bio, North Berwick, Maine, USA and ZeptoMetrix); Japanese Encephalitis Virus (JEV) NS1, E. coli recombinant E (Prospec*); Usutu virus (USUV) NS1.

Techniques:

Journal: Vaccines

Article Title: A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

doi: 10.3390/vaccines9121492

Figure Lengend Snippet: Humoral immune responses in mice, immunized with YF-replicons. ( A ) Schematic representation of the experimental design. ( B – D ) YFV-NS1-specific, ( E , F ) MERS-CoV S1-specific and ( G ) SARS-CoV S1-specific IgG antibodies, as measured by ELISA and expressed as endpoint titers. ( H – J ) Neutralizing titers against MERS-CoV ( H , I ) and against mouse-adapted SARS-CoV strain MA15 and a human-derived SARS-CoV strain Fr-1 ( J ) as measured by virus neutralization test and expressed as endpoint titers. The dotted lines indicate the lowest detectable titer (detection limit of the assay). All symbols represent individual titer values, and the geometric means are shown with horizontal lines. The YF-replicon used as a vaccine is shown above each graph. Statistical analysis was performed with nonparametric ANOVA ( B – D ) and with a t -test ( E , F , H – J ). Differences with p values ≤ 0.05 were considered significant and are shown where relevant. On the x-axis, days post-prime vaccination are shown.

Article Snippet: Mouse anti-YFV-NS1 monoclonal antibody (BioFront Technologies, Tallahassee, FL, USA, BF-087) was used as a positive control for the YFV NS1-based ELISA, while SARS-CoV hyperimmune serum kindly provided by Dr. Bart Haagmans (Erasmus MC, Rotterdam, The Netherlands) was used as a positive control for the SARS S1-based ELISA.

Techniques: Enzyme-linked Immunosorbent Assay, Derivative Assay, Virus, Neutralization